Literature DB >> 12461803

New paclitaxel-cisplatin based chemotherapy regimen for advanced stage, recurrent, or refractory neuroblastoma-preliminary report.

Giammarco Surico1, Paola Muggeo, Francesco De Leonardis, Nicola Rigillo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12461803     DOI: 10.1002/mpo.10106

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


× No keyword cloud information.
  2 in total

1.  HsMAD2 mRNA expression may be a predictor of sensitivity to paclitaxel and survival in neuroblastoma.

Authors:  Kohei Otake; Keiichi Uchida; Kouji Tanaka; Yuhki Koike; Mikihiro Inoue; Kohei Matsushita; Motoko Ueeda; Kiyoshi Hashimoto; Takahito Kitajima; Yoshihiro Komada; Masato Kusunoki
Journal:  Pediatr Surg Int       Date:  2011-02       Impact factor: 1.827

2.  Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376).

Authors:  James I Geller; Donna Wall; John Perentesis; Susan M Blaney; Mark Bernstein
Journal:  Pediatr Blood Cancer       Date:  2009-03       Impact factor: 3.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.